Immunochemical studies on the differential binding properties of two monoclonal antibodies reacting with Tn red cells.
Two monoclonal antibodies (MoAbs), BRIC 66 (IgM) and BRIC 111 (IgG1), were produced by immunizing mice with ovarian cyst blood group A1 glycoprotein and Tn red cells (RBCs), respectively. Their specificities were determined by inhibitions using Tn sialoglycoproteins (SGPs), mucins (armadillo [ASG] and ovine [OSG] submaxillary glycoproteins), and monosaccharides. BRIC 66 agglutinated both Tn and group A RBCs and reacted immunohistochemically with both the vascular endothelium and tumor cells from a group A adenocarcinoma, BRIC 66 was inhibited by N-acetylgalactosamine (GalNAc), Tn SGPs, and mucins on both hemagglutination inhibition tests and radioimmunoassay. BRIC 111 agglutinated Tn RBCs only, and it specifically stained tumor cells from a group O patient's breast carcinoma and a group A patient's adenocarcinoma. In hemagglutination inhibition tests, BRIC 111 was readily inhibited by Tn SGPs, only partially inhibited by GalNAc, and not inhibited by mucins. In a sensitive radioimmunoassay, BRIC 111 was inhibitable by GalNAc. Tn SGP was 2000-fold more effective as an inhibitor than the mucins (ASG and desialized OSG), which contain a high content of terminal alpha-GalNAc-O-serine (threonine) residues. It is postulated that BRIC 66 is specific for terminal alpha-GalNAc units in carbohydrate chains. The exclusive reaction of BRIC 111 with Tn SGP indicates a combining site larger than GalNAc alpha-1, which probably includes amino acid residues in juxtaposition to GalNAc in Tn SGP. In view of its specific agglutination of Tn RBCs, BRIC 111 is a useful reagent for the examination of polyagglutinable RBCs.
King
M J
MJ
Blood Group Reference Laboratory, Bristol, UK.
Parsons
S F
SF
Wu
A M
AM
Jones
N
N
D000017:ABO Blood-Group System / Q000276:immunology; D000042:Absorption; D000116:Acetylgalactosamine / Q000494:pharmacology; D000230:Adenocarcinoma / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000951:Antigens, Neoplasm / Q000032:analysis / Q000276:immunology*; D015295:Antigens, Tumor-Associated, Carbohydrate; D001943:Breast Neoplasms / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D006023:Glycoproteins / Q000276:immunology / Q000494:pharmacology; D006384:Hemagglutination; D006801:Humans; D007124:Immunoenzyme Techniques; D009077:Mucins / Q000494:pharmacology; D019158:N-Acetylneuraminic Acid; D009439:Neuraminidase / Q000494:pharmacology; D010048:Ovarian Cysts / Q000276:immunology; D010084:Oxidation-Reduction; D010504:Periodic Acid; D012794:Sialic Acids / Q000276:immunology; D012795:Sialoglycoproteins / Q000276:immunology
D000017:ABO Blood-Group System; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D006023:Glycoproteins; D009077:Mucins; D012794:Sialic Acids; D012795:Sialoglycoproteins; C040286:Tn antigen; D010504:Periodic Acid; D009439:Neuraminidase; D019158:N-Acetylneuraminic Acid; D000116:Acetylgalactosamine